Press Releases

Pulmonary Drug Delivery Devices Market at a notable CAGR of 4.4% during the forecast period of 2017 to 2030

Share This Article

Global Pulmonary Drug Delivery Systems Market: Snapshot

Pulmonary drug delivery systems refer to the technologies that are used to treat diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis using pulmonary route of drug administration. While these systems have been in medical use for more than six decades, recent technological advancements in pulmonary drug delivery systems have expanded their potential application in other diseases as well including diabetes, lung cancer, and others. The market for pulmonary drug delivery systems is projected to be worth US$28.7 bn by the end of 2019, propagating at a notable CAGR of 4.4% during the forecast period of 2017 to 2019.

Get the sample copy of report@ https://qyresearchmedical.com/sample/112015

Apart from growing adoption of pulmonary drug delivery as an alternative to route of drug delivery, the market is gaining traction from some of the other factors such as the development of smart and digital inhalers, increasing number of smokers, and growth of the distribution network since the emergence of ecommerce. On the flip side, regulatory hurdles, patent expiration of some of the blockbuster drugs, and issues pertaining to the stability of drugs are some of the restraints hindering the prosperity of the global pulmonary drug delivery systems market. However, the vendors of this market are expected to gain vast new opportunities in the emerging economies of Asia Pacific.

Metered Dore Inhalers Market’s Key Product Segment

On the basis of product type, the pulmonary drug delivery devices market has been segmented into nebulizers, metered dose inhalers (MDI), and dry powder inhaler (DPI). As of 2017, the MDI segment has the maximum demand, providing for a revenue of US$14,512.7 mn. MDIs can be further classified into three categories based on the drugs delivered, namely metered dose inhalers with bronchodilators, corticosteroids, and a combination of both. However, patents of blockbuster drugs such as Advair HFA/Seretide Evohaler and Ventolin HFA/Ventolin Evohaler by GlaxoSmithKline have expired in 2017 and is expected to reflect negatively over the MDI segment. On the other hand, the demand for nebulizers and DPIs have been anticipated multiply profitably during the forecast period of 2017 to 2019.

View full report@ https://qyresearchmedical.com/report/pulmonary-drug-delivery-devices-market-product-type-dry-powder-inhalers-metered-dose-inhalers-and-nebulizers-application-asthma-copd-and-cystic-fibrosis-distribution-channel-retail-pharmacies-hospital-p-017-2030/112015

The report also classifies the pulmonary drug delivery systems market on the basis of application, into COPD, cystic fibrosis, and asthama. The latter provided for a demand worth of US$16,085.9 mn in 2017 and is projected to remain most profitable over the course of next seven years. The analysts of the report have also bifurcated the market on the basis of distribution channel into hospital pharmacies, retail pharmacies, and ecommerce.

Developed and Developing Economies Driving Demand

In terms of region, North America, Europe, and Asia Pacific are the three regions of greatest potential. According to the analysts, the North America pulmonary drug delivery systems market was worth US$10,072.8 mn, gaining traction from factors such as strong prevalence of asthma, consistent focus of the government to reduce treatment costs, and escalating percentage of geriatrics in the U.S. The European market for pulmonary drug delivery systems, which was valued at US$7,059.0 mn in 2017, is driven by the countries of Germany, France, the U.K., Italy, and Spain. Some of the major factors responsible for this stunted growth in Europe include active penetration by generic makers and government austerity measures in key countries to reduce prices. Vastly populated region of Asia Pacific, driven by the emerging economies of China and India, is expected to generate demand for pulmonary drug delivery devices at a robust rate during the forecast period of this report.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112015/2900

AstraZeneca Plc, Novartis AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc, Merck & Co. Inc., and Teva Pharmaceutical Industries Ltd. are a few key players operating in the global pulmonary drug delivery systems market.

TABLE OF CONTENT

1.Preface
1.1.Report Scope
1.2.Market Segmentation
1.3.Research Highlights

2.Assumptions and Research Methodology
2.1.Assumptions
2.2.Research Methodology

3.Executive Summary

4.Market Overview
4.1.Product Type Overview
4.2.Key Industry Events
4.3.Market Opportunity Map

5.Market Dynamics
5.1.Drivers and Restraints Snapshot Analysis
5.2.Drivers
5.3.Restraints
5.4.Opportunity Analysis
5.5.Opportunities
5.6.Trends
5.7.Porter’s Five Forces Analysis
5.8.Value Chain Snapshot

6.Pulmonary Drugs Market Analysis, by Product Type
6.1.Key Findings
6.2.Introduction
6.3.Global Pulmonary Drug Delivery Devices Market Value Share Analysis, by Product Type
6.4.Global Pulmonary Drug Delivery Devices Market Forecast, by Product Type
6.4.1.Global Dry Powder Inhalers (DPIs) Market Revenue (US$ Mn) and Volume (million units), 2014–2024
6.4.2.Global Metered Dose Inhalers (MDIs) Market Revenue (US$ Mn) and Volume (million units), 2014–2024
6.4.3.Global Nebulizers Market Revenue (US$ Mn) and Volume (million units), 2014–2024
6.5.Global Pulmonary Drugs Market Attractiveness Analysis, by Product Type
6.6.Key Trends

7.Pulmonary Drug Delivery Devices Market Analysis, by Application
7.1.Key Findings
7.2.Introduction
7.3.Global Pulmonary Drug Delivery Devices Market Value Share Analysis, By Application, 2016 and 2024
7.4.Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and volume (million units) Forecast, By Application, 2014–2024
7.4.1.Global Asthma Market Revenue (US$ Mn) and volume (million units), 2014–2024
7.4.2.Global COPD Market Revenue (US$ Mn) and volume (million units), 2014–2024
7.4.3.Global Cystic Fibrosis Market Revenue (US$ Mn) and volume (million units), 2014–2024
7.4.4.Global Other Applications Market Revenue (US$ Mn) and volume (million units), 2014–2024
7.4.5.Global Pulmonary Drug Delivery Devices Market Attractiveness By Application
7.5.Key Trends

8.Pulmonary Drug Delivery Devices Market Analysis, by Distribution Channel
8.1.Key Findings
8.2.Introduction
8.3.Global Pulmonary Drug Delivery Devices Market Value Share Analysis, By Distribution Channel, 2016 and 2024
8.4.Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, By Distribution Channel, 2015–2024
8.4.1.Global Retail Pharmacies Market Revenue (US$ Mn) and Volume (million units), 2014–2024
8.4.2.Global Hospital Pharmacies Market Revenue (US$ Mn) and Volume (million units), 2014–2024
8.4.3.Global E-commerce Market Revenue (US$ Mn) and Volume (million units), 2014–2024
8.5.Global Pulmonary Drug Delivery Devices Market Attractiveness by Distribution Channel

9.Pulmonary Drug Delivery Devices Market Analysis, By Region
9.1.Global Scenario
9.2.Global Pulmonary Drug Delivery Devices Market Value Share Analysis By Region, 2016 and 2024
9.3.Global Pulmonary Drug Delivery Devices Market Size (US$ Mn) and Volume (million units) Forecast, By Region, 2016–2024
9.4.Global Pulmonary Drug Delivery Devices Market Attractiveness Analysis, by Region

10.North America Pulmonary Drug Delivery Devices Market Analysis

…….

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/112015/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Show More

Related Articles

Back to top button